HER2在晚期轉(zhuǎn)移性結(jié)直腸癌中的研究進(jìn)展

打開文本圖片集

[關(guān)鍵詞」轉(zhuǎn)移性結(jié)直腸癌;人表皮生長因子受體 2;高通量核苷酸序列分析;循環(huán)腫瘤 DNA;分子靶向治療[中圖分類號(hào)］R735.3 [文獻(xiàn)標(biāo)志碼］A [文章編號(hào)] 2096-5532（2025）03-0465-05doi：10.11712/jms.2096-5532.2025.61.072 [開放科學(xué)（資源服務(wù)）標(biāo)識(shí)碼（OSID）][網(wǎng)絡(luò)出版]https：//link.cnki.net/urlid/37.1517.R.20250627.1107.004； 2025-06-2716：38：44

Research advances inHER2 in advanced metastaticcolorectal cancerZHAO Peipei，WANG Zhihai，LI Mingyue，SUN Shuolan，JUFang（Schoolof Clinical Medicine，Shandong Second Medical University，Weifang 261ooo，China）

[Abstract] Colorectal cancer is a common malignant tumor of the digestive tract，and about 20% of patients have distant me tastases at initial diagnosis，while 5% of metastatic colorectal cancer （mCRC） cases are of the human epidermal growth factor receptor2（HER2）varianttype.HER2-positive mCRC patients who have failed standard treatmentcansignificantly benefit from HER2-targetedtherapy.Thisarticlereviewstherecentresearchadvancesindetectionmethods，diagnosticcriteriaprognosticsig nificance，andtargetedtherapiesforHER2inmCRC，inorder toprovideareferenceforHER2-relateddiagnosisandtreatmentin mCRC patients in clinical practice.

[Key words]metastatic colorectal cancer;humanepidermal growth factorreceptor 2；high-throughput nucleotide sequencing；circulating tumor DNA；molecular targeted therapy

結(jié)直腸癌（CRC）的發(fā)病率和死亡率分別位列全球常見惡性腫瘤的第3位和第2位，在我國的發(fā)病率和死亡率也持續(xù)攀升。（剩余14730字）